Literature DB >> 29904224

The global burden of kidney disease and the sustainable development goals.

Valerie A Luyckx1, Marcello Tonelli2, John W Stanifer3.   

Abstract

Kidney disease has been described as the most neglected chronic disease. Reliable estimates of the global burden of kidney disease require more population-based studies, but specific risks occur across the socioeconomic spectrum from poverty to affluence, from malnutrition to obesity, in agrarian to post-industrial settings, and along the life course from newborns to older people. A range of communicable and noncommunicable diseases result in renal complications and many people who have kidney disease lack access to care. The causes, consequences and costs of kidney diseases have implications for public health policy in all countries. The risks of kidney disease are also influenced by ethnicity, gender, location and lifestyle.  Increasing economic and health disparities, migration, demographic transition, unsafe working conditions and environmental threats, natural disasters and pollution may thwart attempts to reduce the morbidity and mortality from kidney disease. A multisectoral approach is needed to tackle the global burden of kidney disease. The sustainable development goals (SDGs) emphasize the importance of a multisectoral approach to health. We map the actions towards achieving all of the SDGs that have the potential to improve understanding, measurement, prevention and treatment of kidney disease in all age groups. These actions can also foster treatment innovations and reduce the burden of such disease in future generations.

Entities:  

Mesh:

Year:  2018        PMID: 29904224      PMCID: PMC5996218          DOI: 10.2471/BLT.17.206441

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


Introduction

The 17 sustainable development goals (SDGs) were adopted by the United Nations, as successors to the millennium development goals, with the broad goal of achieving healthy people living on a healthy planet. Although only SDG 3, that is, to ensure healthy lives and promote well-being for all at all ages, is specifically focused on health, achievement of all of the SDGs should have health benefits via impacts on the environment, governance and society. The Global action plan for the prevention and control of noncommunicable diseases 2013–2020 (hereafter called the 2013 action plan) outlined an approach to reduce the combined mortality from four major categories of noncommunicable disease, i.e. cancer, cardiovascular disease, chronic respiratory disease and diabetes, by 25% by 2025. Previously, these four categories had been prioritized in the 2008–2013 action plan because, collectively, they were believed to account for about 60% of global deaths and it was anticipated that a large proportion of these deaths could be prevented through elimination of shared risk factors, e.g. alcohol and tobacco use, poor diets and inadequate exercise. Although laudable, the 2013 action plan has been criticized for failing to acknowledge the broader drivers of the noncommunicable disease epidemics, other important noncommunicable diseases and the so-called causes of the causes of noncommunicable diseases and failing to place sufficient emphasis on the need for coordinated multisectoral action. We argue that kidney disease represents one of the important noncommunicable diseases missing from the 2013 action plan and that, given the many social and structural factors that directly affect risks and outcomes of kidney disease, multisectoral action to achieve the SDGs will help prevent and control such disease (Table 1).
Table 1

The 17 sustainable development goals and their relevance to kidney health, 2015

GoalDescriptionRelevance to kidney healthRelevant SDG 3 targets
1End poverty in all its forms everywhereImprovements in access to nutrition, personal safety and health care should enhance the prevention, detection and management of kidney diseaseShould reduce the incidence of catastrophic health expenditure resulting from treatment for kidney disease3.8
2End hunger, achieve food security and improved nutrition and promote sustainable agricultureImprovements in maternal nutrition and reductions in the frequencies of low birth weight and preterm birth should reduce the risk of CKDReductions in the incidence of obesity should cut the risk of CKD, diabetes and hypertension3.1, 3.2
3Ensure healthy lives and promote well-being for all at all agesShould improve screening for, and the prevention, diagnosis and treatment of, kidney diseasePublic health programmes to promote community education, healthy lifestyles and vaccinations could also reduce the risk of AKI and CKDAll
4Ensure inclusive and equitable quality education for all and promote life-long learningShould improve awareness and kidney-health-related knowledgeMay reduce use of nephrotoxic remedies and preparations3.4, 3.5
5Achieve gender equality and empower women and girlsReductions in the numbers of teenage pregnancies and increases in pregnancy spacing may reduce the incidence of the low birth weight, prematurity and pregnancy-related complications that are all risk factors for CKDThere should also be improvements in overall family health3.1, 3.7
6Ensure access to water and sanitation for allThere should be reductions in the incidence of the waterborne diseases and diarrhoeal illnesses that are major causes of AKI and in the incidence of the schistosomiasis that can cause CKDThere should also be reductions in water pollution that can cause CKD3.9
7Ensure access to affordable, reliable, sustainable and modern energy for allShould broaden opportunities to use mobile health in prevention and treatment and in community and health worker educationImprovements in access to electronic information sharing and data collection could lead to improvements in the epidemiology, monitoring and surveillance of kidney disease3.9
8Promote inclusive and sustainable economic growth, employment and decent work for allImprovements in personal access to health care, dignity and wealth could lead to improvements in the prevention and early treatment of kidney diseaseImprovements in the retention of health-care workers could reduce the so-called brain drainTask shifting in health care could be facilitated3.b, 3.c
9Build resilient infrastructure, promote sustainable industrialization and foster innovationCould support innovations to improve the affordability and sustainability of access to diagnosis, facilitate early treatment and secondary prevention and foster cheaper and more efficient means to prevent, diagnose and treat both AKI and CKDCould also facilitate investigation of the potential benefits of, or risks posed by, traditional remedies for kidney disease3.b
10Reduce inequality within and among countriesCould improve equity in the prevention, diagnosis and care of all forms of kidney diseaseCould improve access to expensive therapies, e.g. dialysis, hepatitis C therapy and transplantationCould improve geographical access to all forms of kidney care3.1, 3.2, 3.7, 3.8, 3.b, 3.d
11Make cities inclusive, safe, resilient and sustainableImproved warning and protection from disasters could reduce crush-injury-related AKILevels of preparedness in mass disasters, including for patients with AKI, CKD or ESKD, should improveUrban planning to eliminate food deserts and increase physical activity could help reduce diabetes and obesity-related kidney diseaseReductions in exposure to alcohol, drugs and tobacco could also reduce the risk of kidney disease3.5, 3.6, 3.d
12Ensure sustainable consumption and production patternsPromotion of the environmentally friendly and sustainable local production of dialysis supplies could reduce dialysis costs, create jobs and support the local economyAny reductions in the need for dialysis should reduce the carbon footprint from dialysisThere may also be adverse effects on kidney health as increasing access to cars and unhealthy processed foods could lead to an increasing prevalence of obesity and access to cigarettes may also increase3.4, 3.5, 3.9
13Take urgent action to combat climate change and its impactsGlobal warming may have contributed to an epidemic of Central American nephropathy and to CKD of unknown origin that appears related to dehydration and toxin exposureThe adverse effects of climate change on the transmission of pathogens causing infectious disease and poverty may increase the risk of CKD3.2, 3.3, 3.d
14Conserve and sustainably use the oceans, seas and marine resourcesExposure to marine pollution may increase the risk of CKD3.9, 3.d
15Sustainably manage forests, combat desertification and halt and reverse land degradation and halt biodiversity lossAny reduction in the leaching of toxins from industrial waste into ground water could reduce the risk of the CKD associated with such pollution3.9, 3.d
16Promote just, peaceful and inclusive societiesAny reduction in armed conflict could reduce the risk of AKI associated with crush injuries and major trauma and improve food securityThe incidence of low birth weight, which is a risk factor for CKD, tends to increase during warsAmong prisoners and other marginalized populations, improvements in equity and justice could facilitate the prevention, diagnosis and treatment of kidney disease3.d
17Revitalize the global partnership for sustainable developmentImproved global partnerships for health-care financing and regulation and health-related development and research could accelerate our understanding of kidney disease, reduce inequities in kidney care and reduce so-called transplant tourism3.d

AKI: acute kidney injury; CKD: chronic kidney disease; ESKD: end-stage kidney disease; SDG: sustainable development goal.

AKI: acute kidney injury; CKD: chronic kidney disease; ESKD: end-stage kidney disease; SDG: sustainable development goal.

Global burden

Although often considered a comorbidity of diabetes or hypertension, kidney disease has numerous complex causes. Importantly, such disease has an indirect impact on global morbidity and mortality by increasing the risks associated with at least five other major killers: cardiovascular diseases, diabetes, hypertension, infection with human immunodeficiency virus (HIV) and malaria. For example, the Global Burden of Disease (GBD) 2015 study estimated that 1.2 million deaths, 19 million disability-adjusted life-years (DALYs) and 18 million years of life lost from cardiovascular diseases were directly attributable to reduced glomerular filtration rates., The GBD 2015 study also estimated that, in 2015, 1.2 million people died from kidney failure, an increase of 32% since 2005. In 2010, an estimated 2.3–7.1 million people with end-stage kidney disease died without access to chronic dialysis. Additionally, each year, around 1.7 million people are thought to die from acute kidney injury. Overall, therefore, an estimated 5–10 million people die annually from kidney disease. Given the limited epidemiological data, the common lack of awareness and the frequently poor access to laboratory services, such numbers probably underestimate the true burden posed by kidney disease. It is therefore possible that, each year, at least as many deaths are attributable to kidney disease as to cancer, diabetes or respiratory diseases, three of the four main categories targeted by the 2013 action plan.,, In addition, the estimated number of DALYS attributable to kidney disease globally increased from 19 million in 1990 to 33 million in 2013. In 2016, the DALYs associated with chronic kidney disease, along with those associated with cardiovascular disease, cancers, diabetes and neurological disorders, were found to have increased significantly between 1990 and 2015. A report from the GBD 2016 study highlighted the important omission of focus on chronic kidney disease and suggested that “the SDG agenda offers at best a minimal platform for drawing attention to the health care and monitoring needs of [chronic kidney disease].” Kidney disease is associated with a tremendous economic burden. High-income countries typically spend more than 2–3% of their annual health-care budget on the treatment of end-stage kidney disease, even though those receiving such treatment represent under 0.03% of the total population. In 2010, 2.62 million people received dialysis worldwide and the need for dialysis was projected to double by 2030. Globally, the total cost of the treatment of the milder forms of chronic kidney disease appears to be much greater than the total cost of treating end-stage kidney disease. In 2015, in the United States of America, for example, Medicare expenditures on chronic and end-stage kidney disease were more than 64 billion and 34 billion United States dollars, respectively. Much of the expenditure, morbidity and mortality previously attributed to diabetes and hypertension are attributable to kidney disease and its complications., Worldwide, important risk factors for kidney disease include diarrhoeal diseases, HIV infection, low birth weight, malaria and preterm birth, all of which are also leading global causes of DALYs. Risks of kidney disease span the life-course and environmental, infection and lifestyle etiologies. If risk factors are identified early, acute kidney injury and chronic kidney disease can be prevented and, if kidney disease is diagnosed early, worsening of kidney function can be slowed or averted by inexpensive interventions, several of which are on the World Health Organization’s (WHO’s) so-called best buys list for noncommunicable disease management. Such interventions include counselling for cardiovascular disease, diabetes and hypertension, drug therapy, tobacco control, promotion of physical activity and the reduction of salt intake through legislation and food labelling. The timely identification and management of acute kidney injury and chronic kidney disease represent the most effective strategy to address the growing global burden sustainably., By advocating for a multisectoral approach, as a means to achieving the SDGs, it should be possible to reduce the incidence of kidney disease globally. We discuss the kidney-health-related opportunities offered by attempts to achieve each SDG (Table 1).

SDGs and kidney health

SDGs 1, 3.8, 3.b and 10

In high-income countries, lower socioeconomic status is associated with greater risk of end-stage kidney disease because of behavioural and metabolic risk factors and reduced access to care. In low- and middle-income countries, the burden posed by such poverty-related kidney disease is even greater, because of associated infections, hazardous work, poor education and poor maternal health. In all countries, poverty is associated with lack of social protection and transportation, poor housing and unemployment. Lack of transportation restricts access to care even when treatment costs are not a major barrier. Poverty and lower socioeconomic status have been specifically identified as independent risks for both incident chronic kidney disease and the more rapid progression of such disease. In low-income countries where treatment costs have to be paid directly by patients, a month’s supply of essential medications for the treatment of chronic kidney disease can cost up to 18 days’ wages and the corresponding out-of-pocket costs of dialysis, for acute kidney injury or end-stage kidney disease, are much higher., In South Africa, where limited access to dialysis is government-funded, patients who are otherwise eligible for dialysis are frequently declined access because of their socioeconomic circumstances. For those who do access dialysis, the financial burden is exacerbated because they cannot be employed while receiving dialysis or travelling to and from the provider. Promotion of universal health coverage should reduce the financial hardship of patients with kidney disease and improve access to kidney care. The goal of eradicating poverty spans all of the other SDGs and is fundamental to improving kidney health. In turn, achievement of each SDG promises to promote equity and reduce poverty.

SDG 2

Many low-income countries have problems with undernutrition and overnutrition, both are risk factors for kidney disease. Malnutrition predisposes young children to infections, e.g. diarrhoeal diseases and pneumonia, that are important risk factors for acute kidney injury. Among girls and female adolescents, undernutrition leads to underweight mothers and low-birth-weight offspring. Low birth weights, preterm births and pregnancies affected by diabetes and pre-eclampsia, which, combined, may represent up to 20% of pregnancies worldwide, are all associated with increased lifetime risk of chronic kidney disease in both mothers and children. Obesity increases the lifetime risk of end-stage kidney disease and maternal obesity is associated with adverse outcomes in pregnancy, including the gestational diabetes and preterm births that are associated with increased risk of chronic kidney disease. Adequate nutrition is a key tool for reducing the burden of chronic kidney disease. Groups with very low incomes often live in areas where access to healthful foods is very limited or non-existent. Some population-level strategies, e.g. public education about healthful food choices, regulation of the fat, salt and/or sugar contents of food and the regulation of programmes for the provision of public and/or school meals, can all improve kidney health. Reduction in dietary salt is proposed as a cost-saving best buy with great potential to avert deaths from kidney disease. Similarly, a tax on high-sugar beverages, as introduced in Mexico, where chronic kidney disease is the second leading cause of death, can lead to sustained decreases in the purchase of taxed drinks and may reduce diabetes-related kidney disease over time.

SDG 3

SDG 3 has many links to better kidney health (Table 2 available at: http://www.who.int/bulletin/volumes/96/6/17-206441) including optimization of fetal development, prevention of infections, reduction of the mortality and morbidity of cardiovascular disease and mitigation of environmental exposures. The Global Kidney Health Atlas has provided an overview of the main gaps in kidney care globally: an absence of relevant policies, shortages of essential medications, reliable epidemiological data, relevant workforce capacity, infrastructure and research capacity and a persistent reliance on out-of-pocket payments. The Atlas emphasizes the need for a health-system-wide approach to kidney care and provides a baseline against which to measure progress. Work towards reducing the global burden of kidney disease will contribute to achieving SDG 3 (Table 2).
Table 2

Relevance of the targets of sustainable development goal 3 to kidney disease, 2015

TargetDescriptionRelevant kidney conditionStrategies or actions to reduce risk of kidney diseasePolicies facilitating improved kidney health
3.1By 2030, reduce global maternal mortality to less than 70 deaths per 100 000 live birthsPregnancy-related AKI and pre-eclampsiaImprove access to antenatal care and institutional deliveries and the recognition of pregnancy complications, e.g. eclampsia, pre-eclampsia and peripartum haemorrhageUHCPromotion of gender equityPublic health promotion of healthy lifestyles through education and regulation of unhealthy food and tobacco consumptionPromotion of the consumption of healthy food
Identify, during antenatal care or at delivery, mothers at risk, for education and follow-up to reduce long-term risk of maternal CKD and cardiovascular disease associated with pre-eclampsia
3.2By 2030, end preventable deaths of neonates and children under 5 years of age, with all countries aiming to reduce neonatal mortality to no more than 12 deaths per 1000 live births and mortality among children under 5 years of age to no more than 25 deaths per 1000 live birthsPerinatal AKIReduce prematurityUHCEducation of health-care workersEnhancement of the capacity and infrastructure for detection and surveillance
Avoid or reduce perinatal use of nephrotoxins, e.g. aminoglycoside antibiotics and non-steroidal anti-inflammatory drugs
Optimize neonatal nutrition
CKD and hypertension in later lifeReduce prematurity and low birth weight, which are both risk factors for low nephron numbersUHC to improve access to prevention and screening servicesPublic health promotion of healthy lifestyles through education and regulation of unhealthy food and tobacco consumptionAdoption and implementation of the FCTC
Diarrhoea-associated and HUS-associated AKI, post-infectious glomerulonephritisImprove sanitation and access to vaccinations and medical careDevelopment of public health policy to improve disease surveillance and response to outbreaks
3.3By 2030, end the epidemics of AIDS, malaria, neglected tropical diseases and tuberculosis, and combat hepatitis, waterborne diseases and other communicable diseasesHIV nephropathyProvide equitable access to services for the prevention and treatment of HIV infectionUHCEnactment of protections for women victims of domestic violence and sexual assaultTaking action, including legal, policy and regulatory reforms, to ensure full political enfranchisement for womenLegislation for the protection of sex workers
Malaria-associated AKI, black water feverPrevent and provide early treatment of malaria and combat both availability of fake medication and emergence of resistance to antimalarialsDevelopment of public health policy to improve disease surveillance and response to outbreaksReforming of pharmaceutical supply chains and enhancement of regulations to combat fake medicines
CKD – a risk factor for tuberculosisIncrease awareness of riskDevelopment of public health policy to improve disease surveillance and the effectiveness of diagnosis and treatmentDevelopment of innovative interventions to improve labour conditions and conditions in prisons
Adapt medication doses according to kidney dysfunction
Hepatitis-associated glomerulonephritis and hepatorenal syndromeImprove access to vaccination and treatment for hepatitis B and CProvision of public education and UHCDevelopment of care models integrating traditional healers. Legislation on alcohol consumption to reduce high-risk drinking
Reduce hepatitis-associated inflammation and immune-complex deposition
Reduce kidney-disease-associated cirrhosis and liver failure
CKD from infectionsPrevent and treat Hantavirus, leptospirosis and scrub typhusDevelopment of public health policy to improve disease surveillance and the effectiveness of diagnosis and treatment
Urinary obstructionReduce schistosomiasisDevelopment of public health policy to improve disease surveillance and response to outbreaks
Diagnose and treat kidney tuberculosis adequately, to reduce long-term obstruction of urinary tract
3.4By 2030, reduce by one third premature mortality from noncommunicable diseases through prevention and treatment and promote mental health and well-beingCKDPrevent and screen for CKD, improve access to early diagnosis and effective treatment for CKD, provide equitable access to treatment for kidney failure, i.e. dialysis and transplantation, and strengthen access to options for lifestyle improvementUHCEnactment of protections for women victims of domestic violence and sexual assaultTaking action, including legal, policy and regulatory reforms, to ensure full political enfranchisement for womenPromotion of healthy lifestyles through education and regulation of unhealthy food consumptionAdoption and implementation of FCTCEnhancement of capacity and infrastructure for detection and surveillanceDevelopment of care models integrating traditional healers. Enhancement of occupational safety standardsDevelopment of transparent policies governing access to expensive therapies such as dialysis and transplantation
Reduction in CKD could reduce morbidity and mortality associated with some other diseases, e.g. cancer, diabetes and liver disease
Cardiovascular diseaseReduce CKD, this should reduce the burdens posed by global hypertension and cardiovascular disease and the associated mortality
AKIPrevent AKI through improved access to sanitation and vaccination, decrease reliance on toxic traditional remedies, improve access to early diagnosis and effective treatment for AKI and provide equitable access to dialysis
Reduction in AKI could reduce morbidity and mortality associated with some other conditions, e.g. heart failure, liver disease, sepsis and surgery
3.5Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcoholCKD and hypertension in later lifeReduce low birth weight associated with alcohol use, smoking and substance abuse in pregnancyUHCEnactment of protection for women victims of domestic violence and sexual assaultTaking action, including legal, policy and regulatory policy reforms, to ensure full political enfranchisement for womenPromotion of urban safetyLegislation and regulation of alcohol consumptionAdoption and implementation of FCTCLegislation for the protection of sex workers
Alcohol use and smoking are risk factors for CKD progression
HIV and hepatitis-associated kidney disease, infectious glomerulonephritisReduce infections transmitted by intravenous drug use
RhabdomyolysisPrevent rhabdomyolysis by increasing awareness and providing treatment for drug withdrawal and delirium tremens
3.6By 2020, halve the number of global deaths and injuries from road traffic accidentsAKIPrevent trauma-related crush injury or blunt kidney traumaEnforcement of existing traffic laws and reform of traffic laws to reduce road traumaPromotion of occupational safetyDevelopment and building of infrastructure and safe roads, with capacity to absorb urban growth
CKDPrevent accident-related losses in employment, increases in poverty and reductions in access to health care
3.7By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmesPregnancy-related AKI, CKDEmpower women, increase spacing of pregnancies and reduce teenage pregnanciesPromotion of access to education for all and family planning, gender equity and UHCStrengthen legislation on access to safe abortion and the protection of sex workers
Reduce risk of low birth weight and preterm birth, as these can adversely affect kidney health of the child
3.8Achieve UHC, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for allAKI, CKDProvide universal access to basic health care and services for the diagnosis, prevention and treatment of all kidney disease and its risk factors, e.g. diabetes and hypertensionPromotion of innovative financing, regulation of the pricing of medical products and UHCMonitoring of catastrophic health expenditure
3.9By 2030, substantially reduce the number of deaths and illnesses from hazardous chemicals and air, water and soil pollution and contaminationCKD of unknown origin, observed in Egypt, India and Sri Lanka, and Balkan nephropathyReduce exposure to environmental toxins that may be associated with CKD, e.g. aristolochic acid and cadmium and othersPromotion of environmental protection and safetyPromotion of sustainable agriculture and fishingCommitment to combat climate change
3.aStrengthen the implementation of WHO’s FCTC in all countries, as appropriateCKDReduce tobacco smoking, a risk factor for cardiovascular disease and mortality, haematuria, low birth weight and proteinuriaAdoption and implementation of FCTC
3.bSupport the research and development of vaccines and medicines for the communicable and noncommunicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full, the provisions in the TRIPS Agreement regarding flexibilities to protect public health and, in particular, provide access to medicines for allAKIProvide and support the uptake of vaccines that can prevent diarrhoeal illness, sepsis and other infections that can cause AKI and can prevent low birth weight in pregnancyPromotion of budget allocation for locally relevant researchStrengthening and empowerment of local research ethics committeesUtilization of TRIPS Agreement exemptionsEnhancement of the regulation of generic medicationMonitoring of medication supply and usePromotion of health technology assessmentsDevelopment of transparent policies governing access to expensive therapies, e.g. dialysis and transplantationDevelopment of innovative financing models to reduce costs of dialysis and transplantationImplementation and enforcement of the Istanbul Declaration against organ traffickingDevelopment of legislation regarding brain death and organ donationOpt-out or presumed-consent policies for organ donation
Support prompt access to the intravenous fluid and appropriate antibiotics that can prevent AKI and glomerulonephritisd
Vaccination in pregnancy can reduce the risk of low birth weight
Vaccination during pregnancy can reduce the incidence of low birth weight
CKDProvide affordable and sustainable access to basic medications for CKD, diabetes and hypertension and so reduce burden of end-stage kidney disease
ESKDDevise innovative ways to deliver cheaper dialysis worldwide
TransplantationPromote safe and altruistic kidney donation by living donors. Improve supply from deceased donors where permissible. Stop organ trafficking
3.cSubstantially increase health financing and the recruitment, development, training and retention of the health workforce in developing countries, especially in least developed countries and small island developing statesKidney disease awareness and capacity to treatImprove awareness and capacity to diagnose, prevent and treat kidney diseaseDevelopment of innovative financing models to reduce costs of dialysis and transplantationPromotion of the education, licensing and registration of health-care workers and researchersPromotion of the fair remuneration of health-care workersLegislation to define the scope of practice of community health workers and any associated task shifting
Train and retain health-care workers with knowledge of kidney disease
3.dStrengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risksCrush syndrome
Improve disaster planning and responses to earthquakes and other major disastersPromotion of international collaboration to respond to natural disastersCommitment to equality and peacePromotion of democracyStrengthening of intersectoral communication and collaboration
CKDPromote peace
Prevention of wars should reduce both the burden of kidney disease associated with low birth weight and malnutrition and the conflict-related disruption of care

AIDS: acquired immunodeficiency syndrome; AKI: acute kidney injury; CKD: chronic kidney disease; ESKD; end-stage kidney disease; FCTC: Framework Convention on Tobacco Control; HIV: human immunodeficiency virus; HUS: haemolytic uraemic syndrome; TRIPS: Trade-related Aspects of Intellectual Property Rights; UHC: universal health coverage; WHO: World Health Organization.

AIDS: acquired immunodeficiency syndrome; AKI: acute kidney injury; CKD: chronic kidney disease; ESKD; end-stage kidney disease; FCTC: Framework Convention on Tobacco Control; HIV: human immunodeficiency virus; HUS: haemolytic uraemic syndrome; TRIPS: Trade-related Aspects of Intellectual Property Rights; UHC: universal health coverage; WHO: World Health Organization.

SDGs 4 and 5

Because they are, in general, responsible for most child care and housework, women in low- and middle-income countries may face greater challenges if they have chronic kidney disease – and other noncommunicable diseases, than men with similar health problems. Heavy demands on their time may explain why, even though chronic kidney disease is more common among women than men, fewer women than men receive dialysis. Child marriage and lack of access to family planning contribute to poor maternal health and increased risk of obstetrical complications, including acute kidney injury. Among urban adults in the United States, both gender and race appeared to affect glomerular filtration rates. Achievement of equity for women worldwide should reduce the burden of kidney disease.

SDG 6

Globally, almost 800 million people lack access to safe water and 2.5 billion lack access to optimal sanitation. In low- and middle-income countries, waterborne and pestilent diseases associated with poor hygiene and sanitation are major causes of acute kidney injury and chronic kidney disease. Enteric diarrhoeal deaths, associated with lack of safe water, cause over 1 million deaths annually. Most of these deaths occur in children younger than five years and many can be attributed to dehydration-related acute kidney injury. Non-enteric diseases caused by waterborne pathogens, e.g. leptospirosis and schistosomiasis, are also major causes of kidney disease in low- and middle-income countries. Local availability of clean water would be expected to reduce the risk of diarrhoea-related acute kidney injury. Beyond infection-related kidney complications from contaminated water and poor sanitation, additional challenges exist. Water containing organic perfluoroalkyl acids and heavy metals has been associated with chronic kidney disease in several settings and pesticide-contaminated well water may contribute to the risk of some chronic kidney disease observed in Sri Lanka. Dehydration, in conjunction with heat stress, may have contributed to the epidemic of chronic kidney disease observed among young, economically productive male labourers in Central America and South-East Asia. The global burden of kidney disease should be reduced by ensuring the availability of clean water and adequate sanitation.

SDGs 7 and 12–15

Climate change, degradation of biodiversity, forest and land, and loss of marine resources, all likely increase the risk of kidney disease through multiple mechanisms, e.g. increases in food insecurity, the incidences of heat-related illness and infectious diseases and pollution. Deforestation and land degradation can bring humans into greater contact with vector-borne and waterborne pathogens, such as enteric bacteria and other pathogens that can directly cause kidney disease, e.g. those causing dengue fever, leishmaniasis, leptospirosis, malaria, schistosomiasis, trypanosomiasis and yellow fever. Reducing the global burden of kidney disease in turn will also be critical for mitigating some of the environmental impacts of dialysis. Each year, for example, the haemodialysis given to more than 2 million people requires 160 billion litres of water and generates over 900 000 tonnes of, predominantly plastic waste. Clean, local production of dialysis supplies, the reprocessing of dialysis filters, the reuse of dialysis water, solar-powered dialysis and waterless dialysis are all promising strategies that could creduce the environmental footprint of dialysis as well at its costs.

SDGs 8, 10 and 17

Within low- and middle-income countries, access to dialysis is highly inequitable. Despite its relative cost–effectiveness, access to transplantation is even more inequitable because of cultural, financial and legislative barriers and infrastructural limitations. In the face of extreme social inequalities and a demand for transplants that markedly exceeds the supply, the trafficking of kidneys and other human organs remains a major concern. Disparities in the burden of kidney disease, which are particularly complex, arise from biological, environmental, genetic, lifestyle and sociocultural factors and need to be addressed via multilevel, systematic interventions. An example of the complexities involved has been described in the United States. There, in general, compared with other patients with similar disease, patients with chronic kidney disease from ethnic and racial minorities have delayed referral for care, lower incomes, report poorer physician–patient relationships and have less access to health care in general. The pervasive disparities in kidney disease will have to be addressed before SDGs 8, 10 and 17 can be achieved.

SDGs 3.6, 3.d, 9 and 11

Rapidly occurring urbanization has contributed to the rise of kidney disease and other noncommunicable diseases in low- and middle-income countries. In addition to the commonly associated lifestyle changes, e.g. a switch to high-calorie, sodium-rich diets and decreased physical activity, rapid urbanization has led to crowded cities with environmental pollution, a limited infrastructure and poor levels of sanitation and waste disposal. Such urbanization also means that more and more people are living in settings where a growing prevalence of noncommunicable diseases, e.g. diabetes, hypertension and obesity, is juxtaposed with environmental toxins and numerous infectious diseases. These changes portend a synergistic growth in the global burden of kidney disease. There may already be evidence of such growth in the ever-higher ranking of chronic kidney disease among leading cause of deaths, across all country income categories, between 1990 and 2016. By building resilient infrastructure while promoting sustainable industrialization, it should be possible to enhance health-care access while simultaneously reducing the risk of kidney disease. In low- and middle-income countries, urban planning, to improve hygiene and sanitation and reduce population densities and the transmission of the pathogens causing enteric infections, schistosomiasis and tuberculosis, should reduce the incidence of acute kidney injury and chronic kidney disease. At the same time, by promoting the development of parks, paths and efficient transport systems, urban planning could increase general levels of physical activity and so help reduce the risk of obesity-related kidney disease. The effective prevention of chronic kidney disease will require engagement with the corporate sector, whose interests may be in conflict with those of public health. Novel strategies are required to create incentives for the corporate sector to promote public health. Even under optimal circumstances, kidney disease cannot always be prevented and strategies to reduce the economic, physical and social burdens of end-stage kidney disease are needed. Innovative mechanisms to reduce dialysis costs and make dialysis less dependent on electricity and water could multiply opportunities for access to dialysis, especially in low- and middle-income countries. Innovation is also required to improve access to transplantation. Although opt-out or presumed-consent strategies have been proposed as a way of increasing the supply of organs from deceased donors, they remain contentious. Acute kidney injury after a road-traffic collision may result from rhabdomyolysis and multi-organ failure as well as blunt or penetrating kidney injury. Natural disasters are associated with increased rates of crush-injury-induced acute kidney injury and frequently lead to life-threatening interruptions of treatment among those with end-stage kidney disease. Similarly, forced migrants with chronic or end-stage kidney disease can face dangerous interruptions in their treatment or receive inadequate care, even in a high-income country such as the United States. Continued action on reducing the burden of road-traffic injuries and supporting efforts to integrate noncommunicable disease management into humanitarian relief efforts should help to reduce the burden of chronic and end-stage kidney disease.

SDG 16

Exposure to armed conflict can result in acute kidney injury caused by crush injury and rhabdomyolysis and the severity of injuries sustained in combat strongly correlates with the subsequent risk of chronic kidney disease. Kidney disease is common in incarcerated populations and, in terms of their kidney health, prisoners may face a triple burden: of excess risk of kidney disease and its risk factors, of barriers to preventive care for established chronic kidney disease and of the suboptimal management of end-stage kidney disease. As an important step towards improving global health, much work is required globally to reduce conflict and disparities and enhance peace.

Policy perspective

The net health burden of kidney disease is substantial, growing and driven by complex interactions, between communicable and noncommunicable diseases, that are shaped by upstream environmental and socioeconomic disparities. Although kidney disease, whether acute, chronic or end-stage, can be extremely costly, it is also potentially preventable and adverse outcomes can often be delayed or prevented by inexpensive interventions. Kidney disease is highly prevalent, spans the life course and has substantial financial implications. Our response to such disease requires a systematic policy approach, to strengthen all relevant aspects of the health system and to facilitate integration of the promotion of kidney health within a comprehensive horizontal programme for the prevention and treatment of noncommunicable diseases (Table 2). Within each country, the local burden and prevalence of kidney disease and its risk factors and the local capacity to identify and manage such disease must be determined, as a prerequisite for fair priority setting and appropriate policy development. Diagnosis of kidney disease is often hampered by a lack of awareness among health-care workers and at-risk communities and by inadequate and often erratic access to laboratory testing. Broad policies are increasingly being adopted globally to curb dietary intakes of fat, salt and sugar. Such policies all promise to reduce the burden of chronic kidney disease. The burden of acute kidney injury could be reduced through the ongoing commitment to reduce the transmission of the pathogens causing infectious diseases. We need universal health coverage to tackle kidney disease successfully and ensure effective screening, prevention and early treatment. Effective and transparent policies to govern access to care for end-stage kidney disease should only be developed after there has been a thorough attempt to determine the local health priorities, especially in resource-poor settings. Engagement with all relevant stakeholders and innovative financing strategies will be required to maximize equitable access to care. The bidirectional and synergistic interplay between kidney disease and all of the SGDs must be acknowledged in the development of a multisectoral approach. Policies that foster domestic and international collaboration, improve occupational and road safety, limit organ trafficking, promote access to education and gender equality, reduce unemployment and tackle the predicted adverse effects of climate change may all reduce kidney disease and/or the disparities in the care for such disease. However, as noted by the United Nations Secretary-General in December 2017, in the control and prevention of noncommunicable diseases, “political commitments have not often been translated into concrete action.” On its own, policy-making is insufficient. Monitoring the impact of policies on kidney disease and the risk factors for such disease needs to be integrated into existing surveillance activities. Health workers and communities must be empowered to advocate for, and hold policy-makers accountable for, kidney health, as an important step towards achievement of the SDGs.
  37 in total

1.  Effect of besiegement on non-communicable diseases: haemodialysis.

Authors:  Majd Isreb; Mohamad Alyousef; Nada Obaid; Aula Abbara; Mohamed Sekkarie
Journal:  Lancet       Date:  2016-11-12       Impact factor: 79.321

Review 2.  City planning and population health: a global challenge.

Authors:  Billie Giles-Corti; Anne Vernez-Moudon; Rodrigo Reis; Gavin Turrell; Andrew L Dannenberg; Hannah Badland; Sarah Foster; Melanie Lowe; James F Sallis; Mark Stevenson; Neville Owen
Journal:  Lancet       Date:  2016-09-23       Impact factor: 79.321

3.  Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.

Authors:  Marcello Tonelli; Paul Muntner; Anita Lloyd; Braden J Manns; Scott Klarenbach; Neesh Pannu; Matthew T James; Brenda R Hemmelgarn
Journal:  Lancet       Date:  2012-06-19       Impact factor: 79.321

Review 4.  Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.

Authors:  Adeera Levin; Marcello Tonelli; Joseph Bonventre; Josef Coresh; Jo-Ann Donner; Agnes B Fogo; Caroline S Fox; Ron T Gansevoort; Hiddo J L Heerspink; Meg Jardine; Bertram Kasiske; Anna Köttgen; Matthias Kretzler; Andrew S Levey; Valerie A Luyckx; Ravindra Mehta; Orson Moe; Gregorio Obrador; Neesh Pannu; Chirag R Parikh; Vlado Perkovic; Carol Pollock; Peter Stenvinkel; Katherine R Tuttle; David C Wheeler; Kai-Uwe Eckardt
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

Review 5.  Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis.

Authors:  Gabriela Cobo; Manfred Hecking; Friedrich K Port; Isabella Exner; Bengt Lindholm; Peter Stenvinkel; Juan Jesús Carrero
Journal:  Clin Sci (Lond)       Date:  2016-07-01       Impact factor: 6.124

Review 6.  On-plot drinking water supplies and health: A systematic review.

Authors:  Alycia Overbo; Ashley R Williams; Barbara Evans; Paul R Hunter; Jamie Bartram
Journal:  Int J Hyg Environ Health       Date:  2016-04-19       Impact factor: 5.840

7.  The Impact of Kidney Development on the Life Course: A Consensus Document for Action.

Authors: 
Journal:  Nephron       Date:  2017-03-21       Impact factor: 2.847

Review 8.  A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010.

Authors:  Katherine T Mills; Yu Xu; Weidong Zhang; Joshua D Bundy; Chung-Shiuan Chen; Tanika N Kelly; Jing Chen; Jiang He
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

9.  Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet       Date:  2017-09-16       Impact factor: 79.321

10.  Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition.

Authors:  Christopher J L Murray; Ryan M Barber; Kyle J Foreman; Ayse Abbasoglu Ozgoren; Foad Abd-Allah; Semaw F Abera; Victor Aboyans; Jerry P Abraham; Ibrahim Abubakar; Laith J Abu-Raddad; Niveen M Abu-Rmeileh; Tom Achoki; Ilana N Ackerman; Zanfina Ademi; Arsène K Adou; José C Adsuar; Ashkan Afshin; Emilie E Agardh; Sayed Saidul Alam; Deena Alasfoor; Mohammed I Albittar; Miguel A Alegretti; Zewdie A Alemu; Rafael Alfonso-Cristancho; Samia Alhabib; Raghib Ali; François Alla; Peter Allebeck; Mohammad A Almazroa; Ubai Alsharif; Elena Alvarez; Nelson Alvis-Guzman; Azmeraw T Amare; Emmanuel A Ameh; Heresh Amini; Walid Ammar; H Ross Anderson; Benjamin O Anderson; Carl Abelardo T Antonio; Palwasha Anwari; Johan Arnlöv; Valentina S Arsic Arsenijevic; Al Artaman; Rana J Asghar; Reza Assadi; Lydia S Atkins; Marco A Avila; Baffour Awuah; Victoria F Bachman; Alaa Badawi; Maria C Bahit; Kalpana Balakrishnan; Amitava Banerjee; Suzanne L Barker-Collo; Simon Barquera; Lars Barregard; Lope H Barrero; Arindam Basu; Sanjay Basu; Mohammed O Basulaiman; Justin Beardsley; Neeraj Bedi; Ettore Beghi; Tolesa Bekele; Michelle L Bell; Corina Benjet; Derrick A Bennett; Isabela M Bensenor; Habib Benzian; Eduardo Bernabé; Amelia Bertozzi-Villa; Tariku J Beyene; Neeraj Bhala; Ashish Bhalla; Zulfiqar A Bhutta; Kelly Bienhoff; Boris Bikbov; Stan Biryukov; Jed D Blore; Christopher D Blosser; Fiona M Blyth; Megan A Bohensky; Ian W Bolliger; Berrak Bora Başara; Natan M Bornstein; Dipan Bose; Soufiane Boufous; Rupert R A Bourne; Lindsay N Boyers; Michael Brainin; Carol E Brayne; Alexandra Brazinova; Nicholas J K Breitborde; Hermann Brenner; Adam D Briggs; Peter M Brooks; Jonathan C Brown; Traolach S Brugha; Rachelle Buchbinder; Geoffrey C Buckle; Christine M Budke; Anne Bulchis; Andrew G Bulloch; Ismael R Campos-Nonato; Hélène Carabin; Jonathan R Carapetis; Rosario Cárdenas; David O Carpenter; Valeria Caso; Carlos A Castañeda-Orjuela; Ruben E Castro; Ferrán Catalá-López; Fiorella Cavalleri; Alanur Çavlin; Vineet K Chadha; Jung-Chen Chang; Fiona J Charlson; Honglei Chen; Wanqing Chen; Peggy P Chiang; Odgerel Chimed-Ochir; Rajiv Chowdhury; Hanne Christensen; Costas A Christophi; Massimo Cirillo; Matthew M Coates; Luc E Coffeng; Megan S Coggeshall; Valentina Colistro; Samantha M Colquhoun; Graham S Cooke; Cyrus Cooper; Leslie T Cooper; Luis M Coppola; Monica Cortinovis; Michael H Criqui; John A Crump; Lucia Cuevas-Nasu; Hadi Danawi; Lalit Dandona; Rakhi Dandona; Emily Dansereau; Paul I Dargan; Gail Davey; Adrian Davis; Dragos V Davitoiu; Anand Dayama; Diego De Leo; Louisa Degenhardt; Borja Del Pozo-Cruz; Robert P Dellavalle; Kebede Deribe; Sarah Derrett; Don C Des Jarlais; Muluken Dessalegn; Samath D Dharmaratne; Mukesh K Dherani; Cesar Diaz-Torné; Daniel Dicker; Eric L Ding; Klara Dokova; E Ray Dorsey; Tim R Driscoll; Leilei Duan; Herbert C Duber; Beth E Ebel; Karen M Edmond; Yousef M Elshrek; Matthias Endres; Sergey P Ermakov; Holly E Erskine; Babak Eshrati; Alireza Esteghamati; Kara Estep; Emerito Jose A Faraon; Farshad Farzadfar; Derek F Fay; Valery L Feigin; David T Felson; Seyed-Mohammad Fereshtehnejad; Jefferson G Fernandes; Alize J Ferrari; Christina Fitzmaurice; Abraham D Flaxman; Thomas D Fleming; Nataliya Foigt; Mohammad H Forouzanfar; F Gerry R Fowkes; Urbano Fra Paleo; Richard C Franklin; Thomas Fürst; Belinda Gabbe; Lynne Gaffikin; Fortuné G Gankpé; Johanna M Geleijnse; Bradford D Gessner; Peter Gething; Katherine B Gibney; Maurice Giroud; Giorgia Giussani; Hector Gomez Dantes; Philimon Gona; Diego González-Medina; Richard A Gosselin; Carolyn C Gotay; Atsushi Goto; Hebe N Gouda; Nicholas Graetz; Harish C Gugnani; Rahul Gupta; Rajeev Gupta; Reyna A Gutiérrez; Juanita Haagsma; Nima Hafezi-Nejad; Holly Hagan; Yara A Halasa; Randah R Hamadeh; Hannah Hamavid; Mouhanad Hammami; Jamie Hancock; Graeme J Hankey; Gillian M Hansen; Yuantao Hao; Hilda L Harb; Josep Maria Haro; Rasmus Havmoeller; Simon I Hay; Roderick J Hay; Ileana B Heredia-Pi; Kyle R Heuton; Pouria Heydarpour; Hideki Higashi; Martha Hijar; Hans W Hoek; Howard J Hoffman; H Dean Hosgood; Mazeda Hossain; Peter J Hotez; Damian G Hoy; Mohamed Hsairi; Guoqing Hu; Cheng Huang; John J Huang; Abdullatif Husseini; Chantal Huynh; Marissa L Iannarone; Kim M Iburg; Kaire Innos; Manami Inoue; Farhad Islami; Kathryn H Jacobsen; Deborah L Jarvis; Simerjot K Jassal; Sun Ha Jee; Panniyammakal Jeemon; Paul N Jensen; Vivekanand Jha; Guohong Jiang; Ying Jiang; Jost B Jonas; Knud Juel; Haidong Kan; André Karch; Corine K Karema; Chante Karimkhani; Ganesan Karthikeyan; Nicholas J Kassebaum; Anil Kaul; Norito Kawakami; Konstantin Kazanjan; Andrew H Kemp; Andre P Kengne; Andre Keren; Yousef S Khader; Shams Eldin A Khalifa; Ejaz A Khan; Gulfaraz Khan; Young-Ho Khang; Christian Kieling; Daniel Kim; Sungroul Kim; Yunjin Kim; Yohannes Kinfu; Jonas M Kinge; Miia Kivipelto; Luke D Knibbs; Ann Kristin Knudsen; Yoshihiro Kokubo; Soewarta Kosen; Sanjay Krishnaswami; Barthelemy Kuate Defo; Burcu Kucuk Bicer; Ernst J Kuipers; Chanda Kulkarni; Veena S Kulkarni; G Anil Kumar; Hmwe H Kyu; Taavi Lai; Ratilal Lalloo; Tea Lallukka; Hilton Lam; Qing Lan; Van C Lansingh; Anders Larsson; Alicia E B Lawrynowicz; Janet L Leasher; James Leigh; Ricky Leung; Carly E Levitz; Bin Li; Yichong Li; Yongmei Li; Stephen S Lim; Maggie Lind; Steven E Lipshultz; Shiwei Liu; Yang Liu; Belinda K Lloyd; Katherine T Lofgren; Giancarlo Logroscino; Katharine J Looker; Joannie Lortet-Tieulent; Paulo A Lotufo; Rafael Lozano; Robyn M Lucas; Raimundas Lunevicius; Ronan A Lyons; Stefan Ma; Michael F Macintyre; Mark T Mackay; Marek Majdan; Reza Malekzadeh; Wagner Marcenes; David J Margolis; Christopher Margono; Melvin B Marzan; Joseph R Masci; Mohammad T Mashal; Richard Matzopoulos; Bongani M Mayosi; Tasara T Mazorodze; Neil W Mcgill; John J Mcgrath; Martin Mckee; Abigail Mclain; Peter A Meaney; Catalina Medina; Man Mohan Mehndiratta; Wubegzier Mekonnen; Yohannes A Melaku; Michele Meltzer; Ziad A Memish; George A Mensah; Atte Meretoja; Francis A Mhimbira; Renata Micha; Ted R Miller; Edward J Mills; Philip B Mitchell; Charles N Mock; Norlinah Mohamed Ibrahim; Karzan A Mohammad; Ali H Mokdad; Glen L D Mola; Lorenzo Monasta; Julio C Montañez Hernandez; Marcella Montico; Thomas J Montine; Meghan D Mooney; Ami R Moore; Maziar Moradi-Lakeh; Andrew E Moran; Rintaro Mori; Joanna Moschandreas; Wilkister N Moturi; Madeline L Moyer; Dariush Mozaffarian; William T Msemburi; Ulrich O Mueller; Mitsuru Mukaigawara; Erin C Mullany; Michele E Murdoch; Joseph Murray; Kinnari S Murthy; Mohsen Naghavi; Aliya Naheed; Kovin S Naidoo; Luigi Naldi; Devina Nand; Vinay Nangia; K M Venkat Narayan; Chakib Nejjari; Sudan P Neupane; Charles R Newton; Marie Ng; Frida N Ngalesoni; Grant Nguyen; Muhammad I Nisar; Sandra Nolte; Ole F Norheim; Rosana E Norman; Bo Norrving; Luke Nyakarahuka; In-Hwan Oh; Takayoshi Ohkubo; Summer L Ohno; Bolajoko O Olusanya; John Nelson Opio; Katrina Ortblad; Alberto Ortiz; Amanda W Pain; Jeyaraj D Pandian; Carlo Irwin A Panelo; Christina Papachristou; Eun-Kee Park; Jae-Hyun Park; Scott B Patten; George C Patton; Vinod K Paul; Boris I Pavlin; Neil Pearce; David M Pereira; Rogelio Perez-Padilla; Fernando Perez-Ruiz; Norberto Perico; Aslam Pervaiz; Konrad Pesudovs; Carrie B Peterson; Max Petzold; Michael R Phillips; Bryan K Phillips; David E Phillips; Frédéric B Piel; Dietrich Plass; Dan Poenaru; Suzanne Polinder; Daniel Pope; Svetlana Popova; Richie G Poulton; Farshad Pourmalek; Dorairaj Prabhakaran; Noela M Prasad; Rachel L Pullan; Dima M Qato; D Alex Quistberg; Anwar Rafay; Kazem Rahimi; Sajjad U Rahman; Murugesan Raju; Saleem M Rana; Homie Razavi; K Srinath Reddy; Amany Refaat; Giuseppe Remuzzi; Serge Resnikoff; Antonio L Ribeiro; Lee Richardson; Jan Hendrik Richardus; D Allen Roberts; David Rojas-Rueda; Luca Ronfani; Gregory A Roth; Dietrich Rothenbacher; David H Rothstein; Jane T Rowley; Nobhojit Roy; George M Ruhago; Mohammad Y Saeedi; Sukanta Saha; Mohammad Ali Sahraian; Uchechukwu K A Sampson; Juan R Sanabria; Logan Sandar; Itamar S Santos; Maheswar Satpathy; Monika Sawhney; Peter Scarborough; Ione J Schneider; Ben Schöttker; Austin E Schumacher; David C Schwebel; James G Scott; Soraya Seedat; Sadaf G Sepanlou; Peter T Serina; Edson E Servan-Mori; Katya A Shackelford; Amira Shaheen; Saeid Shahraz; Teresa Shamah Levy; Siyi Shangguan; Jun She; Sara Sheikhbahaei; Peilin Shi; Kenji Shibuya; Yukito Shinohara; Rahman Shiri; Kawkab Shishani; Ivy Shiue; Mark G Shrime; Inga D Sigfusdottir; Donald H Silberberg; Edgar P Simard; Shireen Sindi; Abhishek Singh; Jasvinder A Singh; Lavanya Singh; Vegard Skirbekk; Erica Leigh Slepak; Karen Sliwa; Samir Soneji; Kjetil Søreide; Sergey Soshnikov; Luciano A Sposato; Chandrashekhar T Sreeramareddy; Jeffrey D Stanaway; Vasiliki Stathopoulou; Dan J Stein; Murray B Stein; Caitlyn Steiner; Timothy J Steiner; Antony Stevens; Andrea Stewart; Lars J Stovner; Konstantinos Stroumpoulis; Bruno F Sunguya; Soumya Swaminathan; Mamta Swaroop; Bryan L Sykes; Karen M Tabb; Ken Takahashi; Nikhil Tandon; David Tanne; Marcel Tanner; Mohammad Tavakkoli; Hugh R Taylor; Braden J Te Ao; Fabrizio Tediosi; Awoke M Temesgen; Tara Templin; Margreet Ten Have; Eric Y Tenkorang; Abdullah S Terkawi; Blake Thomson; Andrew L Thorne-Lyman; Amanda G Thrift; George D Thurston; Taavi Tillmann; Marcello Tonelli; Fotis Topouzis; Hideaki Toyoshima; Jefferson Traebert; Bach X Tran; Matias Trillini; Thomas Truelsen; Miltiadis Tsilimbaris; Emin M Tuzcu; Uche S Uchendu; Kingsley N Ukwaja; Eduardo A Undurraga; Selen B Uzun; Wim H Van Brakel; Steven Van De Vijver; Coen H van Gool; Jim Van Os; Tommi J Vasankari; N Venketasubramanian; Francesco S Violante; Vasiliy V Vlassov; Stein Emil Vollset; Gregory R Wagner; Joseph Wagner; Stephen G Waller; Xia Wan; Haidong Wang; Jianli Wang; Linhong Wang; Tati S Warouw; Scott Weichenthal; Elisabete Weiderpass; Robert G Weintraub; Wang Wenzhi; Andrea Werdecker; Ronny Westerman; Harvey A Whiteford; James D Wilkinson; Thomas N Williams; Charles D Wolfe; Timothy M Wolock; Anthony D Woolf; Sarah Wulf; Brittany Wurtz; Gelin Xu; Lijing L Yan; Yuichiro Yano; Pengpeng Ye; Gökalp K Yentür; Paul Yip; Naohiro Yonemoto; Seok-Jun Yoon; Mustafa Z Younis; Chuanhua Yu; Maysaa E Zaki; Yong Zhao; Yingfeng Zheng; David Zonies; Xiaonong Zou; Joshua A Salomon; Alan D Lopez; Theo Vos
Journal:  Lancet       Date:  2015-08-28       Impact factor: 79.321

View more
  143 in total

1.  Kidney Health for Everyone Everywhere - From Prevention to Detection and Equitable Access to Care.

Authors:  Philip Kam-Tao Li; Guillermo Garcia-Garcia; Siu-Fai Lui; Sharon Andreoli; Winston Wing-Shing Fung; Anne Hradsky; Latha Kumaraswami; Vassilios Liakopoulos; Ziyoda Rakhimova; Gamal Saadi; Luisa Strani; Ifeoma Ulasi; Kamyar Kalantar-Zadeh
Journal:  Kidney Dis (Basel)       Date:  2020-03-11

2.  Chronic kidney disease in low-middle income populations: a call to action for screening and prevention.

Authors:  Anna Paini; Massimo Salvetti; Silvio Caligaris; Francesco Castelli; Maria Lorenza Muiesan
Journal:  Intern Emerg Med       Date:  2018-12-06       Impact factor: 3.397

3.  Why have Non-communicable Diseases been Left Behind?

Authors:  Florencia Luna; Valerie A Luyckx
Journal:  Asian Bioeth Rev       Date:  2020-03-20

Review 4.  Effectiveness of hypoxia-induced factor prolyl hydroxylase inhibitor for managing anemia in chronic kidney disease: a systematic review and meta-analysis.

Authors:  Min Li; Jiarong Lan; Feixia Dong; Peixin Duan
Journal:  Eur J Clin Pharmacol       Date:  2020-11-07       Impact factor: 2.953

5.  Single-Cell Profiling Reveals Sex, Lineage, and Regional Diversity in the Mouse Kidney.

Authors:  Andrew Ransick; Nils O Lindström; Jing Liu; Qin Zhu; Jin-Jin Guo; Gregory F Alvarado; Albert D Kim; Hannah G Black; Junhyong Kim; Andrew P McMahon
Journal:  Dev Cell       Date:  2019-11-04       Impact factor: 12.270

6.  Age, Gender and Diabetes as Risk Factors for Early Mortality in Dialysis Patients: A Systematic Review.

Authors:  Adil M Hazara; Sunil Bhandari
Journal:  Clin Med Res       Date:  2021-02-13

7.  Urogenital Lesions in Nonhuman Primates at 2 National Primate Research Centers.

Authors:  Shannon Kirejczyk; Christopher Pinelli; Olga Gonzalez; Shyamesh Kumar; Edward Dick; Sanjeev Gumber
Journal:  Vet Pathol       Date:  2020-11-19       Impact factor: 2.221

Review 8.  Challenges of access to kidney care for children in low-resource settings.

Authors:  Mignon McCulloch; Valerie A Luyckx; Brett Cullis; Simon J Davies; Fredric O Finkelstein; Hui Kim Yap; John Feehally; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2020-10-01       Impact factor: 28.314

Review 9.  Acute kidney injury.

Authors:  John A Kellum; Paola Romagnani; Gloria Ashuntantang; Claudio Ronco; Alexander Zarbock; Hans-Joachim Anders
Journal:  Nat Rev Dis Primers       Date:  2021-07-15       Impact factor: 52.329

10.  Living donor kidney transplantation: Let's talk about it.

Authors:  Videha Sharma; Reuben Roy; Oana Piscoran; Angela Summers; David van Dellen; Titus Augustine
Journal:  Clin Med (Lond)       Date:  2020-05       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.